摘要
为了探讨降纤酶治疗急性脑梗死的疗效及与治疗时间窗的关系 ,以及该药对患者血液中的血小板聚集功能和纤维蛋白原的影响。将经确诊的急性脑梗死患者 72例分为降纤酶组和丹参组两组。降纤酶组 38例 ,使用降纤酶治疗 ,10单位加入生理盐水 2 5 0mL中静脉滴注 ,每曰 1次 ,连用 3天 ;丹参组 34例 ,使用丹参粉剂治疗 ,0 .4g加入 5 %葡萄糖液 5 0 0mL中静脉滴注 ,每曰 1次 ,连用 14天。两组病例均于用药前后分别测定患者血液中的血小板聚集功能和纤维蛋白原 ,于治疗后 1周末和 4周末评定疗效 ,此时把两组病例根据起病后至用药时间分为 2 4h内和 2 4～ 72h两部分观察其疗效的变化。结果发现 ,降纤酶组用药前血小板聚集率为 6 5 .6 %± 5 .3% ,纤维蛋白原为 4.78± 0 .42g/L ;用药后血小板聚集率为 45 .8%± 4.9% ,纤维蛋白原为 3.16± 0 .35g/L ,用药前后差异极为显著(P <0 .0 0 1)。丹参组用药前血小板聚集率为 6 0 .4%± 1.9% ,用药后为 49.0 %± 10 .3% ,亦有差异 (P <0 .0 1) ;但降纤酶组用药前后的差异明显高于丹参组 (P <0 .0 5 ,P <0 .0 1)。临床疗效观察发现 ,神经功能改善方面 ,在用药 1周末最明显 ,4周末两组比较无显著差异。但在发病 2 4h内用药者 ,4周末降纤酶组的神经功能改善仍优于丹参组。
Aim [WT5”BZ]To investigate the relationship between the clinical effects of defibrase on acute cerebral infarction and the time used, and the effect on the platelet aggregation and fibrinogen in the patient`s blood. [WT5”HZ]Methods [WT5”BZ]Divide the 72 cases of acute cerebral infarction (ACI) confirmed by CT scan into the defibrase group (38 cases) and the Radix Salviae Miltorrhizase (RSM) group (34 cases). The defibrase group were treated with defibrase iv drip of 10 units mixed 250 mL of physiological saline q.d. for 3 days. The RSM group were treated with RSM iv drip of 0.4 g mixed with 250 mL of 5% glucose q.d. for 14 days. The platelet aggregation function and the fibrinogen of the patients` blood were measured both before and after the drug was given. The clinical effects were valved at the end of the 1st week and the 4th week.[WT5”HZ] Results [WT5”BZ]Before the drug was gevin the platelet aggregation rate was 65.6%±5.3% and the fibrinogen was 4.78±0.42 g/L in the defibrase group, after the drug was given, the platelet aggregation rate was 45.8%±4.9% and the fibrinogen was 3.16±0.35 g/L with a significant difference (P<0.001).Before the drug was given the platelet aggregation rate was 60.4%±1.9% in the RSM group, after the drug was given the platelet aggregation rate was 49.0%±10.3% with a significant difference (P<0.01). [WT5”HZ] Conclusions [WT5”BZ] Defibrase is superior to RSM in controlling the platelet aggregation function and decreasing the plasma fibrinogen concentration, which improves the patient`s high viscosity state and prevents the thrombosis.
出处
《中国动脉硬化杂志》
CAS
CSCD
2000年第1期61-63,共3页
Chinese Journal of Arteriosclerosis
关键词
脑梗塞
降纤酶
丹参
血小板聚集
纤维蛋白原
Reptilase/therapeutic use
Cerebral Infarction/therapy
Platelet Aggregation
Fibrinogen
